3,610,210 Heron Therapeutics, Inc. $HRTX Shares Sold by JW Asset Management LLC

JW Asset Management LLC lessened its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 96.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 140,863 shares of the biotechnology company’s stock after selling 3,610,210 shares during the period. Heron Therapeutics comprises about 0.0% of JW Asset Management LLC’s portfolio, making the stock its 29th biggest position. JW Asset Management LLC owned 0.07% of Heron Therapeutics worth $44,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Heron Therapeutics in the second quarter worth approximately $4,503,000. Orbimed Advisors LLC bought a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $7,855,000. Tejara Capital Ltd bought a new position in shares of Heron Therapeutics in the 2nd quarter worth $2,779,000. Pale Fire Capital SE grew its position in Heron Therapeutics by 84.8% in the 1st quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company’s stock valued at $2,173,000 after purchasing an additional 1,246,673 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Heron Therapeutics in the 2nd quarter valued at $445,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Analysts Set New Price Targets

HRTX has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Finally, Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Heron Therapeutics currently has an average rating of “Reduce” and an average price target of $2.00.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $0.33 on Friday. Heron Therapeutics, Inc. has a 12 month low of $0.26 and a 12 month high of $1.57. The company has a current ratio of 2.33, a quick ratio of 1.51 and a debt-to-equity ratio of 32.59. The business’s 50 day simple moving average is $0.33 and its 200 day simple moving average is $0.65. The company has a market cap of $62.01 million, a price-to-earnings ratio of -2.72 and a beta of 1.65.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $35.25 million for the quarter, compared to analysts’ expectations of $37.50 million. Heron Therapeutics had a negative return on equity of 277.36% and a negative net margin of 14.55%. Sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.14 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.